Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has issued an update.
CR Sanjiu reported its unaudited financial results for the first half of 2025, showing a 4.99% increase in revenue to RMB 14.81 billion, but a significant drop in net profit by 24.31% to RMB 1.82 billion. Despite the revenue growth, the decline in net profit and earnings per share indicates challenges in maintaining profitability, which could impact investor confidence and market positioning.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd is a company based in China, primarily engaged in the pharmaceutical industry. It is a subsidiary of China Resources Pharmaceutical Group Limited and is listed on the Shenzhen Stock Exchange.
Average Trading Volume: 11,247,567
Technical Sentiment Signal: Hold
Current Market Cap: HK$33.05B
For an in-depth examination of 3320 stock, go to TipRanks’ Overview page.